Home
Clinical Trials
A Phase II Study of CI-1033 i...

A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer

Last Updated: 2007-05-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

168 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-12-31

Study Completion Date

2005-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

CI-1033 is an experimental drug that acts as an inhibitor of erbB (EGFR) receptors, which may be involved in tumor growth. The primary objective of this study is to assess the antitumor activity of CI-1033 in patients with metastatic breast cancer. Patients with histologically confirmed metastatic (Stage IV) breast cancer and who have received no more than 2 prior cytotoxic chemotherapy regimens are eligible for this study. CI-1033 is administered orally. Patients are required to have blood tests periodically while receiving treatment and will be closely monitored throughout the study for possible side effects and response to treatment. Patients may not have received any prior treatment with other agents that target erbB receptors, including Herceptin (trastuzumab) or Iressa (gefitinib).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CI-1033

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female, at least 18 years of age
* Histologically confirmed diagnosis of breast cancer
* Metastatic (Stage IV) disease
* Progressive or recurrent disease following the most recent therapy
* No more than 2 different, prior cytotoxic chemotherapy regimens for metastatic disease
* At least one measurable target lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) that has not been irradiated
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, determined within 2 weeks prior to randomization
* Estimated life expectancy of \> 12 weeks
* Capable of giving written informed consent
* Capable of swallowing intact CI-1033 capsules
* Capable of understanding and adhering to the protocol requirements
* No prior exposure to CI-1033 or other agents that target the erbB receptor family (such as Herceptin, Iressa, Tarceva, IMC-C225, and EKB-569)
* No known hypersensitivity reaction to tyrosine kinase inhibitors
* Adequate liver, renal, or bone marrow function determined within 2 weeks prior to randomization
* No cytotoxic chemotherapy within 3 weeks prior to baseline disease assessments (6 weeks for nitrosoureas or mitomycin)
* No immunotherapy (including Herceptin) or other biologic therapy within 2 weeks prior to baseline disease assessments
* No hormone therapy (including hormone replacement therapy) within 4 weeks prior to baseline disease assessments (6 weeks for megestrol acetate)
* Patients must have recovered from the acute effects of any radiation therapy or surgery
* No treatment with any other investigational therapy within 4 weeks prior to baseline disease assessments
* No history of any cancer other than the present condition (except nonmelanoma skin cancer or carcinoma in situ of the cervix) within the last 5 years
* No patients with untreated brain metastases or patients that have not recovered from treatment for brain metastases
* No known malabsorption syndrome or other condition that may impair absorption of study medication
* No comorbidity or condition which compromises compliance with this protocol as judged by the investigator or that would significantly complicate interpretation of the safety profile of CI-1033
* No patients having reproductive potential who are not using a method of birth control or who are pregnant or breastfeeding or have a positive pregnancy test during baseline

Exclusion Criteria

Prior exposure to CI-1033 or other agents that target the erbB receptor family; cytotoxic chemotherapy within 3 weeks prior to baseline disease assessments (6 weeks for nitrosoureas or mitomycin); immunotherapy (including Herceptin) or other biologic therapy within 2 weeks prior to baseline disease assessments; hormone therapy (including hormone replacement therapy) within 4 weeks prior to baseline disease assessments; 6 weeks for megestrol acetate (to exclude the possibility of a hormone-withdrawal response); patients with untreated brain metastases.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Review additional registry numbers or institutional identifiers associated with this trial.

1033-011

Identifier Type: -

Identifier Source: org_study_id

A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Study Design

Interventions

CI-1033

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

Pfizer

Principal Investigators

Pfizer CT.gov Call Center

Locations

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site

Pfizer Investigational Site